Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

por Weiner, M., Skoog, L., Fornander, T., Nordenskjöld, B., Sgroi, D. C., Stål, O.
Publicado 2013

Nodes-and-connections RNAi knockdown screening: identification of a signaling molecule network involved in fulvestrant action and breast cancer prognosis

por Miyoshi, N, Wittner, B S, Shioda, K, Hitora, T, Ito, T, Ramaswamy, S, Isselbacher, K J, Sgroi, D C, Shioda, T
Publicado 2015

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial

por Bartlett, J M S, Sgroi, D C, Treuner, K, Zhang, Y, Ahmed, I, Piper, T, Salunga, R, Brachtel, E F, Pirrie, S J, Schnabel, C A, Rea, D W
Publicado 2019

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

por Jerevall, P-L, Ma, X-J, Li, H, Salunga, R, Kesty, N C, Erlander, M G, Sgroi, D C, Holmlund, B, Skoog, L, Fornander, T, Nordenskjöld, B, Stål, O
Publicado 2011